1. Home
  2. JAZZ vs FOUR Comparison

JAZZ vs FOUR Comparison

Compare JAZZ & FOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAZZ
  • FOUR
  • Stock Information
  • Founded
  • JAZZ 2003
  • FOUR 1999
  • Country
  • JAZZ Ireland
  • FOUR United States
  • Employees
  • JAZZ N/A
  • FOUR N/A
  • Industry
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • FOUR Business Services
  • Sector
  • JAZZ Health Care
  • FOUR Consumer Discretionary
  • Exchange
  • JAZZ Nasdaq
  • FOUR Nasdaq
  • Market Cap
  • JAZZ 6.7B
  • FOUR 6.3B
  • IPO Year
  • JAZZ 2007
  • FOUR 2020
  • Fundamental
  • Price
  • JAZZ $107.51
  • FOUR $92.28
  • Analyst Decision
  • JAZZ Strong Buy
  • FOUR Buy
  • Analyst Count
  • JAZZ 12
  • FOUR 21
  • Target Price
  • JAZZ $183.08
  • FOUR $113.37
  • AVG Volume (30 Days)
  • JAZZ 730.8K
  • FOUR 1.4M
  • Earning Date
  • JAZZ 07-30-2025
  • FOUR 08-07-2025
  • Dividend Yield
  • JAZZ N/A
  • FOUR N/A
  • EPS Growth
  • JAZZ 49.21
  • FOUR 99.89
  • EPS
  • JAZZ 7.51
  • FOUR 2.82
  • Revenue
  • JAZZ $4,064,808,000.00
  • FOUR $3,471,500,000.00
  • Revenue This Year
  • JAZZ $6.05
  • FOUR $23.49
  • Revenue Next Year
  • JAZZ $4.68
  • FOUR $20.98
  • P/E Ratio
  • JAZZ $14.35
  • FOUR $32.82
  • Revenue Growth
  • JAZZ 5.76
  • FOUR 27.39
  • 52 Week Low
  • JAZZ $95.49
  • FOUR $57.45
  • 52 Week High
  • JAZZ $148.06
  • FOUR $127.50
  • Technical
  • Relative Strength Index (RSI)
  • JAZZ 45.65
  • FOUR 52.89
  • Support Level
  • JAZZ $106.56
  • FOUR $87.91
  • Resistance Level
  • JAZZ $109.43
  • FOUR $94.22
  • Average True Range (ATR)
  • JAZZ 2.66
  • FOUR 3.03
  • MACD
  • JAZZ -0.16
  • FOUR -0.59
  • Stochastic Oscillator
  • JAZZ 12.27
  • FOUR 45.85

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

About FOUR Shift4 Payments Inc.

Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.

Share on Social Networks: